Delving into the Latest Updates on H1 Influenza Vaccine Delivered by MIMIX MAP(Vaxess Technologies) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza, Human

Inactive Indication-

Originator Organization

Vaxess Technologies, Inc.

Active Organization

Vaxess Technologies, Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

A Phase 1, Randomized, Rater and Subject Blinded Placebo Controlled Study to Evaluate the Safety, Reactogenicity, Tolerability and Immunogenicity of a Standard and a Fractional Dose of H1 Influenza Vaccine Delivered by VX-103 (a MIMIX Microneedle Patch (MAP) System) in Healthy Adults ≥18-39 Years of Age

A Phase 1, Randomized, Rater and Participant Blinded Placebo Controlled Study to Evaluate the Safety, Reactogenicity, Tolerability and Immunogenicity of a Standard and a Fractional Dose of H1 Influenza Vaccine Delivered by VX-103 (a MIMIX Microneedle Array Patch (MAP) System) in Healthy Adults ≥18-39 Years of Age

Start Date02 Jul 2022

Sponsor / Collaborator

Vaxess Technologies, Inc.

[+3]

100 Clinical Results associated with H1 Influenza Vaccine Delivered by MIMIX MAP(Vaxess Technologies)

Login to view more data

100 Translational Medicine associated with H1 Influenza Vaccine Delivered by MIMIX MAP(Vaxess Technologies)

Login to view more data

100 Patents (Medical) associated with H1 Influenza Vaccine Delivered by MIMIX MAP(Vaxess Technologies)

Login to view more data

100 Deals associated with H1 Influenza Vaccine Delivered by MIMIX MAP(Vaxess Technologies)

Login to view more data